Treatment of the Cystoid Macular Oedema in Behçet's Disease with Interferon Alfa-2a
Deuter C. M. E.1, Kötter I.2, Günaydin I.2, Zierhut M.1, Stübiger N.1
1University Eye Hospital, Dept. I, Tuebingen; 2 University Medical Clinic, Dept. II, Tuebingen
Purpose: Ocular involvement is present in 60-80 % of patients with Behçet's disease (BD). Beside an occlusive vasculitis visual prognosis is limited especially by the cystoid macular oedema which is often refractive to therapy with conventional immunosuppressants. The purpose of this study was to investigate the effect of IFN alfa-2a to the cystoid macular oedema in ocular BD.
Method: We treated 28 patients (female:male = 8:20) suffering from panuveitis or posterior uveitis with uni- or bilateral cystoid macular oedema due to complete BD with IFN alfa-2a (initial dosage 6 Mio. IU per day subcutaneously). Other immunosuppressants were discontinued on the day before start of IFN, steroids were reduced to a maximum dosage of 10 mg prednisolone per day.
Results: At initiation of IFN-therapy 45 eyes showed a cystoid macular oedema proven by fluorescein angiography. In every case there was a complete resorption of macular oedema after a mean of two to four weeks after begin of IFN-treatment without the need for additional application of carboanhydrase inhibitors. Measurements performed by Optical Coherence Tomography (OCT) showed that the effect of IFN to the cystoid macular oedema begins within a few days.
Conclusions: In our study IFN
Zurück | Back